Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STN1011402 eyelid cream in Chinese patients with allergic conjunctivitis
CTR20254908Phase 3Active
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of epinastine in allergic conjunctivitis (AC) (2 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Change from baseline in mean ocular itching score at Day 15 (Visit 4) and Change from baseline in mean conjunctival hyperemia score at Day 15 (Visit 4). Started Jan 2026; status: active.
02
Drugs
epinastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on CTR20254908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254908.